BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.

PARP inhibition is known to be an effective clinical strategy in BRCA mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors. Here, we show the synergy of BET bromodomain inhibition with PARP inhibition in BRCA-proficient ovarian cancers due to mitotic catastrophe. Treatment of BRCA-proficient ovarian cancer cells with the BET inhibitor JQ1 downregulated the G2-M cell-cycle checkpoint regulator WEE1 and the DNA-damage response factor TOPBP1. Combining PARP inhibitor Olaparib with the BET inhibitor, we observed a synergistic increase in DNA damage and checkpoint defects, which allowed cells to enter mitosis despite the accumulation of DNA damage, ultimately causing mitotic catastrophe. Moreover, JQ1 and Olaparib showed synergistic suppression of growth of BRCA-proficient cancer in vivo in a xenograft ovarian cancer mouse model. Our findings indicate that a combination of BET inhibitor and PARP inhibitor represents a potential therapeutic strategy for BRCA-proficient cancers.

[1]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[2]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[3]  J. Schellens,et al.  Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer , 2017, Clinical Cancer Research.

[4]  I. Shih,et al.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. , 2016, The American journal of pathology.

[5]  Chris Mungall,et al.  AmiGO: online access to ontology and annotation data , 2008, Bioinform..

[6]  Mark Morgan,et al.  Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models , 2016, Clinical Cancer Research.

[7]  S. Knapp,et al.  Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.

[8]  Benjamin G. Bitler,et al.  HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci , 2016, The Journal of cell biology.

[9]  V. Beral,et al.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer , 2015, Nature Reviews Cancer.

[10]  I. Screpanti,et al.  PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma , 2017, Oncogene.

[11]  M. Wempe,et al.  A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells. , 2016, ACS chemical biology.

[12]  D. Backos,et al.  Targeting WEE1 Kinase in Cancer. , 2016, Trends in pharmacological sciences.

[13]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[14]  A. Carr,et al.  TopBP1: A BRCT-scaffold protein functioning in multiple cellular pathways. , 2014, DNA repair.

[15]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[16]  Parantu K. Shah,et al.  Targeting Poly(ADP-Ribose) Polymerase and the c-Myb–Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer , 2014, Science Signaling.

[17]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[18]  J. Bartek,et al.  TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity , 2016, The Journal of cell biology.

[19]  Benjamin G. Bitler,et al.  BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. , 2016, Cancer research.

[20]  P. Gestraud,et al.  Histo‐genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non‐BRCAness high grade ovarian carcinoma , 2015, International journal of cancer.

[21]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[22]  J. Schellens,et al.  Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. , 2010, Current clinical pharmacology.

[23]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[24]  Lin Zhang,et al.  Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition , 2017, Science Translational Medicine.